Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : effets secondaires stomatologiques (mucites, épistaxis), Bull. Cancer, vol.98, issue.3, pp.117-126, 2011. ,
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors, J. Am. Acad. Dermatol, vol.55, issue.4, pp.657-670, 2006. ,
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial, Lancet Oncol. 2016 mars, vol.17, issue.3, pp.378-388 ,
Benign migratory glossitis or geographic tongue: an enigmatic oral lesion, Am. J. Med, vol.15, issue.9, pp.751-755, 2002. ,
,
, Mise au point sur l'inhibition de la voie Ras-MAPK : les inhibiteurs de Mek, Bull, vol.99, issue.9, pp.865-874
Inhibiteurs de mTOR : de l'explication biologique à l'application thérapeutique en hématologie, Bull. Cancer (Paris), vol.98, issue.8, pp.935-943, 2011. ,
The structural basis for mTOR function, Semin. Cell Dev. Biol, vol.2014, pp.91-101 ,
Traitements anti-angiogéniques en pratique et dans le futur en oncologie thoracique, Rev. Mal. Respir. Actual, vol.4, issue.6, pp.604-614, 2012. ,
Inhibiteurs de l'angiogenèse : revues de l'apport thérapeutique du sorafenib, du sunitinib et du bevacizumab dans le cancer du rein métastatique, Bull. Cancer (Paris), vol.97, issue.2, pp.29-43, 2010. ,
,
, Ann. Dermatol. Vénéréologie. 2011 mars, vol.138, issue.3, pp.201-208
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases, Br. J. Cancer, vol.107, issue.10, pp.1665-1671, 20126. ,
Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review. The Oncologist, vol.17, pp.135-144, 2012. ,
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, N. Engl. J. Med, vol.9, issue.6, pp.567-578, 2006. ,
The epidermal growth factor, Cell Biol. Int, vol.19, issue.5, pp.413-430, 1995. ,
Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires, Gastroentérologie Clin. Biol, vol.33, issue.4, pp.306-322, 2009. ,
Thérapies ciblées dans le traitement des cancers colorectaux métastatiques : place actuelle, févr, vol.148, pp.12-19, 2011. ,
Mucites radio-induites buccopharyngées : actualités sur la prise en charge. Cancer/Radiothérapie. 2012 sept, vol.16, pp.358-363 ,
Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer, Clin. Colorectal Cancer. 2012 mars, vol.11, issue.1, pp.53-59 ,
Everolimus in the management of metastatic neuroendocrine tumours, Ther. Adv. Gastroenterol, vol.10, issue.1, pp.132-141, 2017. ,
Mécanismes de résistance aux inhibiteurs de BRAF, Ann. Dermatol. Vénéréologie, vol.141, issue.11, pp.671-681, 2014. ,
Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone, Oncology, vol.76, issue.3, pp.209-211, 2009. ,
Rôle de la voie PI3KAKT-mTOR dans le cancer et les thérapeutiques antitumorales, Bull. Cancer, vol.99, issue.2, pp.173-180 ,
Signalisation cellulaire et cancer : caractérisation de cibles thérapeutiques, Pathol. Biol. 2012 août, vol.60, issue.4, pp.217-222 ,
VEGF-receptor signal transduction, Trends Biochem. Sci, vol.28, issue.9, pp.488-494, 2003. ,
Les inhibiteurs des récepteurs de l'Epidermal Growth Factor (EGF). Rev. Médecine Interne, juin, vol.24, issue.6, pp.372-383, 2003. ,
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet, vol.368, issue.9544, pp.1329-1338, 200614. ,
Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, vol.3, issue.1, pp.11-22, 2003. ,
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors, Target. Oncol. 2009 déc, vol.4, issue.4, pp.267-273 ,
Ostéonécrose des maxillaires liée aux bisphosphonates et denosumab : épidémiologie, diagnostic et traitement, Bull. Cancer, vol.102, issue.12, pp.1010-1019 ,
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group, Eur. J. Oncol. Nurs. Off. J. Eur. Oncol. Nurs. Soc. 2012 avr, vol.16, issue.2, pp.172-184 ,
Prevention and Management of Oral Mucositis in Patients With Cancer, Semin. Oncol. Nurs, vol.23, issue.3, pp.201-212, 2007. ,
Clinical Update: Prevention and Management of Oral Mucositis in Patients with Cancer, Semin. Oncol. Nurs, vol.27, issue.4, pp.1-16, 2011. ,
Actualités de la prévention et du traitement des mucites orales chez les enfants cancéreux : recommandations pratiques. Cancer/Radiothérapie. 2016 mai, vol.20, pp.226-230 ,
Oral lichenoid eruption secondary to imatinib (Glivec), J. Dermatol. Treat, vol.15, issue.4, pp.253-255, 2004. ,
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, pp.2144-2150, 2010. ,
The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review, J. Am. Dent. Assoc, vol.145, issue.1, pp.45-56, 1939. ,
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy, J. Hematol. Oncol.J Hematol Oncol, 2010. ,
Characteristics of oral mucosal events related to bevacizumab treatment, The Oncologist, vol.17, issue.2, pp.274-278, 2012. ,
Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N. Engl. J. Med, vol.28, issue.26, pp.2733-2743, 2006. ,
Sorafénib et radiothérapie dans le carcinome hépatocellulaire. Cancer/Radiothérapie. 2011 févr, vol.15, pp.77-80 ,
Historique de la leucémie myéloïde chronique : un paradigme de traitement du cancer*. Bull. Cancer (Paris), janv, vol.101, issue.1, pp.56-67, 2014. ,
Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw, Oral Maxillofac. Surg. Clin. N. Am, vol.27, issue.4, pp.527-536, 2015. ,
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expandedaccess trial, Lancet Oncol. 2009 août, vol.10, issue.8, pp.757-763 ,
Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck, Health Technol. Assess. Winch. Engl, vol.13, issue.1, pp.49-54, 2009. ,
Angiogenese des tumeurs. Mecanismes et deroulement, J. Radiol, vol.85, issue.9, p.1375, 2004. ,
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial, Lancet Oncol. 2016 mars, vol.17, issue.3, pp.357-366 ,
Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience, Clin. Oncol. 2014 mars, vol.26, issue.3, pp.135-141 ,
Review of epidermal growth factor receptor biology, Int. J. Radiat. Oncol, vol.59, issue.2, pp.21-26, 2004. ,
Les inhibiteurs de BRAF et leurs applications potentielles en pédiatrie, Rev. Oncol. Hématologie Pédiatrique, vol.4, issue.2, pp.113-121, 2016. ,
Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition, Cell. Signal, vol.19, issue.10, pp.2003-2012, 2007. ,
Geographic Tongue Induced by Angiogenesis Inhibitors. The Oncologist, janv, vol.4, issue.4, pp.16-17, 2013. ,
BRAF gene: From human cancers to developmental syndromes, Saudi J. Biol. Sci. 2015 juill, vol.22, issue.4, pp.359-373 ,
Epidermal growth factor receptor: mechanisms of activation and signalling, Exp. Cell Res, vol.10, issue.1, pp.31-53, 2003. ,
Updated clinical practice guidelines for the prevention and treatment of mucositis, Cancer. 2007 mars, vol.1, issue.5, pp.820-831 ,
Osteonecrosis of the jaw related to everolimus: a case report, Br. J. Oral Maxillofac. Surg. 2013 déc, vol.51, issue.8, pp.302-304 ,
, Ann. Endocrinol, vol.68, issue.6, pp.45-56, 2007.
Clinical practice guidelines for the prevention and treatment of EGFR inhibitorassociated dermatologic toxicities, Support. Care Cancer. 2011 août, vol.1, issue.8, pp.1079-1095 ,
Anti-TNF alpha dans le traitement de la polyarthrite rhumatoïde et de la spondylarthrite ankylosante. Presse Médicale, vol.38, pp.774-787, 2009. ,
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, Br. J. Dermatol, vol.161, issue.5, pp.1045-1051, 2009. ,
, , vol.2, pp.187-205, 2005.
Lichen plan et dermatoses lichénoïdes, vol.2, pp.132-146 ,
Mucosal Pigmentation Caused by Imatinib: Report of Three Cases, Head Neck Pathol, vol.31, issue.2, pp.290-295, 2011. ,
Intérêt clinique des mutations de BRAF dans le cancer colorectal, Bull, vol.97, issue.12, pp.1441-1452 ,
Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor, Future Oncol. Lond. Engl. 2013 juin, vol.9, issue.6, pp.909-913 ,
Mucosal pigmentation of the hard palate in a patient taking imatinib, BMJ Case Rep, 2015. ,
Roles for VEGF in the adult, Microvasc. Res, vol.74, issue.2-3, pp.100-113, 2007. ,
Leucémie myéloïde chronique et inhibiteurs de tyrosine kinase, vol.22, pp.894-899 ,
A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients, Oral Oncol. 2013 avr, vol.49, issue.4, pp.293-298 ,
Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2011 mai, vol.111, pp.12-16 ,
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, vol.11, issue.2, pp.121-128, 2010. ,
Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med, vol.22, issue.8, pp.722-731, 2013. ,
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review, Drug Resist. Updat. 2011 juin, vol.14, issue.3, pp.177-190 ,
Inhibiteurs de mTOR : de la transplantation à l'oncologie (Revue de la littérature du Comité de Transplantation-AFU 2006). Prog. En Urol, vol.17, pp.928-933, 2007. ,
Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012 févr, vol.113, pp.234-238 ,
Vascular endothelial growth factor family of ligands and receptors: Review, Blood Cells. Mol. Dis, vol.38, issue.3, pp.258-268, 2007. ,
Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients, J. Cranio-Maxillofac. Surg. 2016 mars, vol.44, issue.3, pp.265-270 ,
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol, vol.17, issue.5, pp.577-589, 2016. ,
Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases, Int. J. Dermatol, vol.45, issue.12, pp.1471-1473, 2006. ,
Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up, Ann. Oncol, pp.139-151, 2015. ,
Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique: survie globale et analyse de sous-groupes de l'étude ATHENA France, Bull. Cancer, vol.101, issue.9, pp.780-788 ,
Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor. Actas Dermo-Sifiliográficas Engl, vol.105, pp.655-662, 2014. ,
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study, Lancet Oncol, vol.15, issue.6, pp.569-579, 2014. ,
Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma, Oral Oncol, vol.47, issue.10, pp.984-987, 2011. ,
Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer, Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol, vol.90, issue.2, pp.172-176, 2009. ,
Report: Treatment of geographic tongue with topical tacrolimus, BMJ Case Rep, 2014. ,
Vascular endothelial growth factor receptors: Molecular mechanisms of activation and therapeutic potentials, Exp. Eye Res, vol.83, issue.5, pp.1005-1016, 2006. ,
Inhibiteurs de mTOR : temsirolimus et évérolimus dans le traitement du cancer du rein, Bull. Cancer (Paris), vol.97, issue.2, pp.45-51, 2010. ,
Dépistage des cancers buccaux ,
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer, Oncogene. 2007 mai, vol.14, issue.22, pp.3291-3310 ,
A Rare Case of Melanosis of the Hard Palate Mucosa in a Patient with Chronic Myeloid Leukemia. Case Rep. Dent, 2015. ,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol. 2012 mars, vol.13, issue.3, pp.239-246 ,
Medicationrelated osteonecrosis of the jaw: Clinical and practical guidelines, J. Int. Soc. Prev. Community Dent. 2016 avr, vol.6, issue.2, pp.97-104 ,
VEGF receptor protein-tyrosine kinases: Structure and regulation, Biochem. Biophys. Res. Commun, vol.375, issue.3, pp.287-291, 2008. ,
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update, J. Oral Maxillofac. Surg, vol.72, issue.10, pp.1938-1956, 20141. ,
Un regard simple sur la biologie du cancer bronchique : EGFR, Rev. Mal. Respir, vol.28, issue.4, pp.565-577, 2011. ,
From mediators of cell death and inflammation to therapeutic giants-past, present and future, Cytokine Growth Factor Rev. 2014 août, vol.25, issue.4, pp.453-472 ,
Common toxicities of mammalian target of rapamycin inhibitors, Target. Oncol. 2011 juin, vol.1, issue.2, pp.125-129 ,
Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients, Cancer, vol.1, issue.1, pp.210-215, 2010. ,
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial, Lancet Oncol. 2015 août, vol.16, issue.8, pp.897-907 ,
Le facteur de croissance épidermique: structure, localisation, phosphorylation et régulation de son récepteur, Biochimie, vol.66, issue.7-8, pp.515-530, 1984. ,
Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.10, issue.11, pp.1899-1905, 2009. ,
Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer, mars, vol.15, issue.6, pp.1286-1299, 2009. ,
Schémas de prescription alternatif du sunitinib dans le cancer du rein métastatique: de l'underground au grand public?, Bull. Cancer, vol.101, issue.9, pp.832-840 ,
Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis, Crit. Rev. Oncol. Hematol, vol.71, issue.1, pp.12-21, 2009. ,
Aphtes et ulcérations buccales. Presse Médicale. 2016 févr, vol.45, pp.215-226 ,
Variations physiologiques de la langue, Ann. Dermatol. Vénéréologie, vol.142, issue.10, pp.583-592, 2015. ,
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support. Care Cancer Off, J. Multinatl. Assoc. Support. Care Cancer, 2017. ,
Oral complications of targeted cancer therapies: a narrative literature review, Oral Oncol, vol.47, issue.6, pp.441-448, 2011. ,
, Int. J. Biochem. Cell Biol, vol.31, issue.6, pp.637-643, 1999.
Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer, Clin. Ther, vol.30, issue.1, pp.14-30, 2008. ,
Advanced hepatocellular carcinoma treated by a combination of sorafenib and radiotherapy, Adv. Dig. Med. 2014 mars, vol.1, issue.1, pp.25-29 ,
Oral and Cutaneous Lichenoid Eruption with Nail Changes Due to Imatinib Treatment in a Chinese Patient with Chronic Myeloid Leukemia, Ann. Dermatol. 2015 avr, vol.1, issue.2, pp.228-229 ,
Squamous Cell Cancer of the Head and Neck ,
, Haute Autorité de Santé-VECTIBIX (panitumumab), anticorps monoclonal
, Haute Autorité de Santé-PERJETA (pertuzumab), anticorps monoclonal
, Haute Autorité de Santé-AVASTIN (bevacizumab), anticorps monoclonal
, Haute Autorité de Santé-AFINITOR (évérolimus)
, Cell Death and Differentiation-Tumor necrosis factor signaling, 20156.
, Haute Autorité de Santé-ZELBORAF (vemurafenib), inhibiteur de la protéine kinase BRAF
, anti MEK inhibiteur de protéine kinase
Texte imprimé] : de la clinique au traitement, Paris : Éd. Med'com. cop, 2009. ,
, Table des matières
,
,
, , vol.17
, , p.17
EGF (epidermal growth factor) ,
1.3.1 Molécules ciblant le récepteur EGFR (anticorps monoclonaux), p.22 ,
,
Pertuzumab (Perjeta®)[116] ,
23 1.1.3.2.1 Gefitinib (Iressa®[117]) ,
,
,
31 1.2.3.2.1 Sorafenib (Nexavar®)[121] ,
33 1.3.1 mTOR (mammalian target of rapamicyne) ,
,
,
,
,
,
,
,
,
, 5.5.2 Vemurafenib (Zelboraf®)
,
,
,
,
,
,
,
,
,
Molécules anti RANKL : dénosumab (Prolia®, Xgeva®) ,
,
,
,
,
65 2.1.4.1 Définition et description clinique ,
67 2.1.5.1 Définition et description clinique[106] ,
,
,
, , vol.72
,
,
,
,
,
,
,
, Diagnostic différentiel des pathologies pigmentaires
,
,
,
,
,
,
,
,
3.1.1 Prise en charge des mucites de bas grade ,
, OSTÉOCHIMIONÉCROSES
, , vol.101
,
, 5.3 Soins chirurgicaux chez les patients à risque d'OCN
,
,
, Nancy 2017 : 123 pages, vol.34
, , 2017.
, Mots clés : thérapies ciblées, cancer, recommandations, prise en charge Résumé
, iidè:lll : LM. MARTRETTE-Profes.~ur de.c; Unh'e:n.ités Juges : J. GUH...LEi-T lllBAULT-MaitredeConfércnccsdcs Un1,?e. âtés F. MASCH LN Docteur en Chirurgie Oc:nrnioe P. HlRTZ-A blmll Hospitalier UnÎ\'Cr!\ht1irc
~· isu1111e Ho-11>italier Universitaire Thèse pour obtenir le diplôme o~Etat <le Docteur en Chirurgie Dentaire Présentée par. l\Ionsicur FR CK EAienne ,
, Le 18 anar, 1986.